228 related articles for article (PubMed ID: 32638532)
1. The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX.
Wilmot HV; Rakowski K; Gray E
Int J Lab Hematol; 2020 Dec; 42(6):810-818. PubMed ID: 32638532
[TBL] [Abstract][Full Text] [Related]
2. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
[TBL] [Abstract][Full Text] [Related]
3. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
[TBL] [Abstract][Full Text] [Related]
4. One-Stage Factor VIII Assays.
Duncan E; Rodgers S
Methods Mol Biol; 2017; 1646():247-263. PubMed ID: 28804834
[TBL] [Abstract][Full Text] [Related]
5. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
Ingerslev J; Jankowski MA; Weston SB; Charles LA;
J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
[TBL] [Abstract][Full Text] [Related]
6. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
Pickering W; Hansen M; Kjalke M; Ezban M
J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
[TBL] [Abstract][Full Text] [Related]
8. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
[TBL] [Abstract][Full Text] [Related]
9. Calibration of the WHO 5th IS for Blood Coagulation Factor IX, Concentrate and Ph. Eur. Human Coagulation Factor IX Concentrate Biological Reference Preparation Batch 3 and investigation of the suitability of an IS as potency standard for purified full-length recombinant FIX.
Gray E; Hogwood J; Dougall T; Rigsby P; Matejtschuk P; Terao E
Pharmeur Bio Sci Notes; 2021; 2021():26-68. PubMed ID: 33783349
[TBL] [Abstract][Full Text] [Related]
10. Performance evaluation of Revohem
Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
[TBL] [Abstract][Full Text] [Related]
11. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
Marlar RA; Strandberg K; Shima M; Adcock DM
Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899
[TBL] [Abstract][Full Text] [Related]
13. Influence of factor VIII:C and factor IX activity in plasmas of haemophilic dogs on the activated partial thromboplastin time measured with two commercial reagents.
Mischke R
Haemophilia; 2000 May; 6(3):135-9. PubMed ID: 10792470
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments.
Bowyer AE; Gosselin RC
Semin Thromb Hemost; 2023 Sep; 49(6):609-620. PubMed ID: 36473488
[TBL] [Abstract][Full Text] [Related]
15. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
Rosén P; Rosén S; Ezban M; Persson E
J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience.
Hegemann I; Koch K; Clausen WHO; Ezban M; Brand-Staufer B
Acta Haematol; 2020; 143(5):504-508. PubMed ID: 31639805
[TBL] [Abstract][Full Text] [Related]
17. Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent.
Wilmot HV; Gray E
Haemophilia; 2018 Sep; 24(5):e363-e368. PubMed ID: 30051554
[TBL] [Abstract][Full Text] [Related]
18. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
20. A cost-effective approach to factor assay calibration using a truncated live calibration curve.
Guy S; Sermon-Cadd AM; Shepherd FM; Kitchen S; Bowyer AE
Int J Lab Hematol; 2019 Oct; 41(5):679-683. PubMed ID: 31421012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]